The constructed nanoparticles showed reduced systemic toxicity of cisplatin (CDDP) without compromising its in vivo antitumor activity.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: